AGHDA: Adult Growth Hormone Deficiency Assessment
Adult Growth Hormone Deficiency Assessment Scale · Also known as: AGHDA-25
The AGHDA is a 25-item disease-specific quality of life questionnaire designed to assess the burden of adult growth hormone (GH) deficiency. Developed by Hunt, Werther, and colleagues in 2000, it evaluates symptoms and functional impairments directly related to GH deficiency, including fatigue, reduced muscle strength, weight gain, and psychological difficulties. The instrument is widely used in endocrinology practice and clinical trials to quantify the impact of GH replacement therapy.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
AGHDA is primarily used to: (1) Identify symptomatic adult GH deficiency in patients post-pituitary surgery, radiation, or with childhood-onset GH deficiency now in adulthood; (2) Support diagnostic assessment by documenting symptom burden when biochemical tests are borderline or equivocal; (3) Quantify quality of life improvement during GH replacement therapy to guide dose adjustments and evaluate treatment response; (4) Measure outcomes in clinical trials testing novel GH secretagogues or replacement regimens. Appropriate for adults 18+ with confirmed or suspected GH deficiency. Less useful in patients with multiple pituitary hormone deficiencies without GH deficiency, where broader pituitary quality of life instruments are preferred.
Strengths & limitations
- Disease-specific relevance: AGHDA focuses exclusively on symptoms and impacts of GH deficiency, with high sensitivity to GH replacement-related improvements that generic quality of life measures may miss.
- Simplicity and brevity: 25 yes/no items require minimal time and cognitive effort; suitable for routine clinical screening and follow-up.
- Strong responsiveness: AGHDA demonstrates good sensitivity to GH replacement therapy effects, with documented score reductions of 5-10 points corresponding to clinically meaningful dose increases.
- Wide clinical adoption: Validated in multiple languages; used as primary outcome measure in major GH replacement trials and recommended by endocrinology guidelines for outcome assessment.
- Yes/no format lacks granularity: Binary responses do not capture symptom severity or frequency; items such as 'fatigue' do not distinguish mild from incapacitating fatigue.
- Limited subscale structure: AGHDA yields only a total score; no subscales to identify predominant symptom domains (physical vs. psychological) or guide targeted interventions.
- Moderate overlap with depression/anxiety: Psychological items (mood, concentration, energy) correlate with general mental health questionnaires, making it difficult to isolate GH-specific from comorbid affective symptoms.
- Ceiling effects in mild disease: Patients with borderline GH deficiency often score 8-12, with limited room for improvement score-wise; may underestimate quality of life benefits in this group.
Frequently asked
What is the recommended cutoff score for suspected GH deficiency?
A score ≥11 suggests clinically significant GH deficiency and warrants diagnostic testing (GH stimulation tests, IGF-1 measurement). However, AGHDA is not diagnostic; biochemical confirmation via GH provocative testing and IGF-1 is required. Scores of 8-11 warrant clinical consideration in symptomatic patients but do not definitively indicate GH deficiency.
How quickly does AGHDA improve after starting GH therapy?
Improvements typically appear within 3-6 months; maximum response usually achieved by 12-24 months. Early improvements (3 months) include energy and mood; later improvements (6-12 months) include physical strength and weight reduction. Dose optimization is critical; inadequate dosing may produce minimal AGHDA improvement despite normalized IGF-1 levels.
Can AGHDA distinguish GH deficiency from other pituitary hormone deficiencies?
Partially. AGHDA is most specific for GH deficiency; however, patients with multiple pituitary deficiencies (ACTH, TSH, gonadotropins) show similar symptom profiles (fatigue, weight gain, mood disturbance). Combined AGHDA with assessment of other pituitary axes (8 a.m. cortisol, TSH, testosterone/estrogen) is recommended for full characterization.
Is AGHDA appropriate for children or adolescents?
No. AGHDA was developed and validated for adults ≥18 years. Pediatric GH deficiency is assessed via growth deceleration, auxology, and GH stimulation testing; quality of life questionnaires specific to childhood GH deficiency (e.g., parent-reported measures) are used for this age group.
Sources
- Hunt, A. E., Werther, G. A., & Wrightson, P. (2000). The utility of AGHDA in identifying GH-deficient adults. Clin Endocrinol (Oxf), 52(3), 341-346. link ↗
- Abs, R., Feldt-Rasmussen, U., Mattsson, A. F., et al. (1999). Assessment of GH status in adults with childhood-onset GH deficiency. Clin Endocrinol (Oxf), 50(4), 457-463. link ↗
How to cite this page
ScholarGate. (2026, June 3). Adult Growth Hormone Deficiency Assessment Scale. ScholarGate. https://scholargate.app/en/endocrinology/growth-hormone-deficiency-scale
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- AddiQoLEndocrinology↔ compare
- Diabetes Symptom ChecklistEndocrinology↔ compare
- ThyPROEndocrinology↔ compare